引用本文:[点击复制]
[点击复制]
【打印本页】 【在线阅读全文】【下载PDF全文】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 1328次   下载 1326 本文二维码信息
码上扫一扫!
益生菌防治小儿反复呼吸道感染的临床研究
霍开明1,颜海峰1,黄学晓1,庄秀娟1,王艳2,朱中元1,殷俊德1,谢延群1,韩栋光1
0
(1. 海南医学院第二附属医院,海南海口 570311;2. 海南省三亚市中医院,海南三亚 572000)
摘要:
目的:探讨益生菌对小儿反复呼吸道感染(RRTIs)的防治效果及不良反应。 方法:选择 2014 年 1 月至 2016 年 1 月海南医学院第二附属医院门诊收治的 RRTIs 患儿 85 例,采用前瞻性、随机、双盲、安慰剂对照的方法分为益生菌组 43 例和安慰剂组42 例。 益生菌组给予益生菌片(每片重 0.5 g,含双歧杆菌、嗜酸乳杆菌均≥0.5×10^6 CFU)2 片,3 次/ 日,口服 3 个月;安慰剂组给予安慰剂(片剂外观、口味与益生菌片相同但无益生菌成分),用法同益生菌组。 治疗后两组患儿均随访观察 12 个月,并详细记录两组患儿治疗前后的呼吸道感染次数、抗生素使用及咳嗽、发热、患病天数和药物不良反应等情况。 结果:疗程结束后随访 12 个月,益生菌组与安慰剂组年呼吸道感染次数分别为(3.8±1.6)次、(7.3±1.8)次,抗生素使用时间分别为(12.1±5.6)d、(22.6±7.1)d,咳嗽时间分别为(11.6±4.6)d、(20.3±6.7)d,发热时间分别为(6.4±2.3)d、(13.5±4.2)d,患病时间分别为(13.2±6.0)d、(23.4±7.8)d,两组患儿比较差异均有统计学意义(P 均<0.05)。 两组患儿均未见明显药物不良反应。 结论:益生菌防治小儿 RRTIs 具有较高的安全性,可以减少呼吸道感染次数,减少抗生素使用、咳嗽、发热和患病天数。
关键词:  益生菌  儿童  反复呼吸道感染
DOI:10.13407/j.cnki.jpp.1672-108X.2018.05.004
基金项目:海南省卫生厅 2013 年度医学科研课题资助项目,琼卫 2013 资助-041 号
Prevention and Treatment of Probiotics in Children with Recurrent Respiratory Tract Infections
Huo Kaiming 1 , Yan Haifeng 1 , Huang Xuexiao 1 , Zhuang Xiujuan 1 , Wang Yan 2 , Zhu Zhongyuan 1 , Yin Junde 1 , Xie Yanqun 1 , Han Dongguang 1
(1. The Second Affiliated Hospital of Hainan Medical University, Hainan Haikou 570311, China; 2.The Traditional Hospital of Sanya City, Hainan Sanya 572000, China)
Abstract:
Objective: To investigate the prevention and treatment, adverse effect of probiotics in children with recurrent respiratory tract infections (RRTIs). Methods: Eighty-five children with RRTIs were selected, and divided into probiotics group (n = 43) and control group (n=42) in a randomly, double-blindly and placebo-controlled trail from the outpatient department in the Second Affiliated Hospital of Hainan Medical University from January 2014 to January 2016. Probiotic tablets were given to the probiotics group, 2 tablets orally, 3 times a day for 3 months (There are more than 0.5×10^6 CFU Bifidobacterium and Lactobacillus in each probiotic tablet,respectively). While the placebo were given to the control group, the same usage as the probiotics group with the same shape, taste of the probiotic tablets, yet without the probiotic ingredient. Both groups were followed up for 12 months after treatment and the times of respiratory infections, days of antibiotics usage, cough and fever, and days of illness, and drug adverse reactions were recorded before and after treatment of the two groups. Results: After following up for 12 months, the times of respiratory infections, days of antibiotics usage, cough, fever due to respiratory infections, and days of illness were (3.8±1.6) times and (7.3±1.8) times, (12.1±5.6) d and (22.6±7.1) d, (11.6±4.6) d and (20.3±6.7) d, (6.4±2.3) d and (13.5±4.2) d, (13.2±6.0) d and (23.4±7.8) d between the treatment group and control group, respectively, and the differences of the two groups were statistically significant (P<0.05). No adverse drug reactions were observed in both groups. Conclusion: Probiotics has the prevention and treatment effect on RRTIs in children, and have high safety. Probiotics can reduce the times of respiratory infections, the days of antibiotics usage, cough, fever and the days of illness.
Key words:  probiotics  children  recurrent respiratory tract infections

用微信扫一扫

用微信扫一扫